Skip to main navigation
Skip to content

t2biosystems-logo

Return to T2 Biosystems Homepage Contact T2 Biosystems

Investor Relations

  • Overview
  • Corporate Governance
  • Press Releases
  • SEC Filings
  • Events & Presentations
  • Annual Reports
  • Investor FAQ
  • Stock Information
    • Historical Price Lookup
    • Investment Calculator
    • Analysts
  • Email Alerts

Tools

  • Print Page
  • RSS Feeds
  • Email Alerts

Press Releases

Keyword Search

Date Title
01/11/22
 T2 Biosystems Announces Preliminary Fourth Quarter and Full Year 2021 Results
01/11/22
 T2 Biosystems Announces the Initiation of the T2Biothreat® Panel Clinical Trial
01/11/22
 T2 Biosystems Announces the Initiation of the T2Resistance® Panel Clinical Trial

T2 Biosystems OVERVIEW

T2 Biosystems, an emerging leader in the field of in vitro diagnostics, is dedicated to saving lives and reducing the cost of healthcare by empowering clinicians to effectively treat patients faster than ever before. T2 Biosystems is focused on addressing critical unmet needs in healthcare starting with sepsis, one of the deadliest and most expensive conditions in hospitals today.

The T2Dx Instrument and T2Candida Panel have received marketing authorization from the U.S. Food and Drug Administration. All other T2 Biosystems products are considered investigational and for research use only.

T2 Biosystems®, T2MR®, T2Candida®, T2Dx®, and T2 Bio® are registered trademarks of T2 Biosystems, Inc. T2HemoStat™, T2Plex™, and T2Bacteria™ are trademarks of T2 Biosystems, Inc.

© 2022 T2 Biosystems, Inc.

JOIN IN ON TWITTER


 

Sitemap

  • T2Direct Diagnostics
  • T2MR Technology
  • Pipeline
  • Our Company
  • Terms of Use & Privacy Policy
  • Conflict Mineral Report
  • Investors
  • T2Blog
  • Technical Support
  • Careers
  • Contact Us
  • Standard Terms & Conditions

Follow Us on Social

  • LinkedIn
  • Twitter